LTRN Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Lantern Pharma Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerLTRN

Market Cap41.3M

Cash RunwayRunway < 6 months

Next Catalyst2027-02-01

Public Research Snapshot

Lantern Pharma Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Putting LP-284 on the Industry RADR (Phase 3) using Small Molecule.

Pipeline

Asset	Indication	Modality	Stage	Public Note
LP-184	n/a	Small Molecule	Preclinical	Public pipeline row
The Harmonic™ Clinical Trial	never smokers	n/a	Phase 2	Public pipeline row
LP-300	n/a	n/a	Phase 2	Public pipeline row
LP-284	relapsed or refractory (R/R) lymphomas and solid tumors	Small Molecule	Phase 2	Public pipeline row
LP-300 for Never-smokers with NSCLC Adenocarcinoma	n/a	n/a	Phase 2	Public pipeline row
LP-100	n/a	n/a	Phase 2	Public pipeline row
Background	n/a	Adc	n/a	Public pipeline row
Putting LP-284 on the Industry RADR	n/a	n/a	Phase 3	Public pipeline row

Catalyst Preview

Company	Ticker	Catalyst	Timing	Asset	Confidence
		Clinical Trial Completion	2027-02-01	STAR-001 (LP-184) will be administered via IV infusion over 30 (± 5) minutes on Day 1 and Day 8 of each 21-day cycle.	Low
		Clinical Trial Completion	2028-11-30	LP-284	Low

Cash Runway Preview

Estimated cash runway: Runway < 6 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT00966914	Phase 3	COMPLETED	540	2013-04
NCT03643107	Phase 2	COMPLETED	15	2021-10-01
NCT05933265	Phase 1 \| Phase 2	RECRUITING	175	2025-02-28
NCT07431216	Phase 1 \| Phase 2	NOT_YET_RECRUITING	68	2027-02-01
NCT06132503	Phase 1	RECRUITING	110	2028-11-30

Scientific Context

asset_name | Background
modality | Adc
asset_name | Irofulven
clinical_stage | Phase 2
clinical_stage | Phase 2

Want the full LTRN research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.